ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204 NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system...

ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been...

Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, is expanding its Scientific Advisory...